DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCorporate Action

Bal Pharma Limited — Alteration Of Capital and Fund Raising-XBRL

NSE 1 hr ago·8 Sept 2026, 11:47 am

BAL Pharma

Bal Pharma Limited has informed stock exchanges about the allotment of its securities. This corporate action indicates the company has issued new shares, likely to raise fresh capital for its business operations.

This development is significant for investors as it alters the company's capital structure. It may dilute the ownership percentage of existing shareholders, but it also signals management's confidence in future growth and their intent to strengthen the company's financial position.

Investors should monitor the specific purpose of this fund raising. If the funds are allocated for strategic expansion or debt reduction, it could be a positive signal. However, it is important to keep an eye on the company's future performance to see if the raised capital yields tangible results.